Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:38 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Melatonin for Adolescent Migraine Prevention Study
NCT03150797 · Amy Gelfand · PHASE2 · terminated · last registry update 2023-10-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient Fund” | – | Registry record, Amy Gelfand |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTNR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-09-03Also stopped (withdrawn): University of Nebraska, Melatonin + Diphenhydramine (NCT03688464)
- 2024-08-23Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Antithrombin-III + Infliximab (NCT02251041)
- 2024-08-22Results posted on the registry: Northwell Health, a drug against MTNR1A (NCT05349188)
- 2024-07-22Phase 3 first posted: Nanjing Chia-tai Tianqing Pharmaceutical, Ramelteon + Ramelteon placebo (NCT06512363)
- 2024-07-19Phase 3 first posted: Sultan Qaboos University, Intervention 1 + Intervention 2 (NCT06509191)
- 2024-07-16Results posted on the registry: James A. Keeney, Diphenhydramine (Benadryl) (NCT03968939)
- 2024-07-05Results posted on the registry: Neurim Pharmaceuticals Ltd., Piromelatine + Placebo (NCT02615002)
- 2024-06-26Phase 3 first posted: Odense University Hospital, Melatonin 10 MG + Placebo (NCT06476392)
- 2024-06-06Results posted on the registry: Stony Brook University, Melatonin and Donepezil (NCT02487082)
- 2024-06-06Also stopped (terminated): Stony Brook University, Melatonin and Donepezil (NCT02487082)
- 2024-05-29Also stopped (terminated): Mayo Clinic, a drug against MTNR1A (NCT05307770)
- 2024-05-08Phase 3 first posted: Beni-Suef University, Myoinositol + Co-Enzyme Q10 (NCT06405204)
- 2024-02-07Results posted on the registry: State University of New York at Buffalo, Melatonin (NCT04474483)
- 2024-02-07Also stopped (terminated): State University of New York at Buffalo, Melatonin (NCT04474483)
- 2024-01-26Also stopped (withdrawn): University of Florida, a drug against MTNR1A (NCT03843008)
- 2024-01-09Also stopped (terminated): Northwestern University, Rozerem + Placebo (NCT00745030)
- 2023-12-19Results posted on the registry: Rush University Medical Center, a drug against MTNR1A (NCT02373189)
- 2023-11-13Results posted on the registry: Brigham and Women's Hospital, a drug against MTNR1A (NCT01863446)
- 2023-10-26Phase 3 first posted: University of Jordan, Placebo + Diazepam (NCT06103188)
- 2023-10-02Phase 3 first posted: Lone Baandrup, Melatonin + Quetiapine (NCT06062953)
- 2023-09-15Results posted on the registry: Vanda Pharmaceuticals, Tasimelteon + Placebo (NCT03373201)
- 2023-09-08Also stopped (terminated): University of Nebraska, Natrol (NCT01033565)
- 2023-07-20Also stopped (withdrawn): AGUNCO Obstetrics and Gynecology Centre, Recombinant FSH (rFSH) (NCT01267604)
- 2023-05-30Also stopped (terminated): Rockefeller University, a drug against MTNR1A (NCT02732288)
- 2023-05-12Phase 3 first posted: Coordinación de Investigación en Salud, Mexico, Melatonin 10 MG (NCT05857046)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision